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PIPELLE ENDOMETRIAL CURETTAGE WITH DILATATION 
AND CURETTAGE IN AUB - COMPARATIVE STUDY 
ABSTRACT 
 
Any type of bleeding with an increase in duration, frequency or 
amount is defined as abnormal uterine bleeding (AUB). AUB affect 10-30 
% of reproductive age women and upto 50% of perimenopausal women. 
Age and reproductive status affect the incidence. Main reason for 
endometrial sampling is to confirm the benign nature of the problem by 
ruling out endometrial carcinoma so that medical and conservative surgery 
can be offered. 
OBJECTIVE  
To compare the results of  histopathological diagnosis of  Pipelle 
sampling with D&C and adequacy of tissue for histopathological diagnosis 
of Pipelle sampling with D&C. To assess the feasibility of  Pipelle type of 
endometrial sampling as an outpatient procedure in AUB. 
METHODOLOGY 
This is a prospective study comparing D&C and Pipelle type of 
endometrial sampling in patients with abnormal uterine bleeding. 100 
cases of AUB attending the outpatient clinic in the department of 
Obstetrics and Gynaecology, Coimbatore medical college, in the period of 
July 2011- July 2012 were enrolled in this study. 
RESULTS 
All patient underwent both Pipelle sampling  and D&C. D&C was 
considered as the definitive procedure for diagnosis. Premenopausal 
patient had menorrhagia as their main complaint. Most of the Post 
menopausal patients had post Menopausal bleeding as their complaint. 
Sufficient sample was obtained in 72 patients and 28 patients had 
insufficient sample in Pipelle. With D&C, sufficient sample was obtained 
in all patients. HPE Report obtained in Pipelle was only 88 %, whereas in 
D&C  it was  100%. 
The most important factor associated with scanty tissue at Pipelle 
sampling was found to be endometrial polyp. There was 100 % sensitivity 
and specificity of Pipelle for diagnosing endometrial carcinoma and 
endometrial  hyperplasia. 
In nulliparous women 40% had tough procedure. Elderly patients ( 
≥50 years) had more inadequate sample rate 53.3%. In premenopausal 
patients HPR was available in 64 patients (91.4%).    
In postmenopausal patients, report was available only in 24 (80%). 
ROC curve gave the  cut –off value for endometrial thickness of 9mm for 
successful histopathology reporting. No major adverse events were 
associated with the procedure. All patients tolerated the procedure well. 
CONCLUSION 
Endometrial sampling using Pipelle device is an easy and convenient 
method of getting tissue diagnosis. The sensitivity and specificity of this 
procedure in detecting endometrial hyperplasia and carcinoma were 
comparable with those of the standard procedure-D&C. Pipelle’s 
sampling failed to detect endometrial polyp. Considering all factors 
together, though Pipelle sampling failed to get sufficient sample in 12% 
of cases, comparing the high specificity in detecting endometrial 
hyperplasia and carcinoma, the cost effectiveness and anesthetic 
morbidity, intra and postoperative complications, Pipelle sampling can be 
used as  an effective screening procedure in the outpatient department. 
KEYWORDS  
Abnormal Uterine Bleeding  (AUB), Menopause, Histopathology, Pipelle, 
Dilatation and Curettage.  
 
 INTRODUCTION 
 Any type of bleeding with an increase in duration, frequency or 
amount is defined as abnormal uterine bleeding (AUB). AUB affect        
10-30 % of reproductive age women and upto 50% of perimenopausal 
women
1
.Age and reproductive status affect the incidence. Main reason for 
endometrial sampling is to confirm the benign nature of the problem by 
ruling out endometrial carcinoma so that medical and conservative surgery 
can be offered. 
A detailed history and physical examination are fundamental for 
workup of AUB
2,3
. Women presenting with perimenopausal abnormal 
uterine bleeding, postmenopausal bleeding or history of chronic 
anovulation  are at high risk of developing endometrial pathology. Hence 
in these patients endometrial sampling for histopathological evaluation 
becomes mandatory. Various methods of endometrial sampling are used in 
practice. Dilatation and curettage (D&C) still remains the most common 
endometrial sampling method in India. It is the commonest invasive 
method. But there are short term and long term complications associated 
with the procedure. An alternative for D&C is office endometrial biopsy, 
which does not require cervical dilatation and hence can be done as an 
outpatient procedure without anesthesia. 
 By using outpatient procedure of endometrial sampling we can 
reduce the cost and complications associated with conventional D&C. Of 
the several endometrial sampling methods, Pipelle device has been found 
to be very comfortable and gave comparable histological findings from 
tissue obtained by D&C or hysterectomy. Since 1980 the most popular 
device is disposable Pipelle that was first introduced in France. It is semi 
rigid plastic tube with single side opening having a diameter of 3.1mm. It 
can be inserted without cervical dilatation. So it is an ideal device for 
outpatient setting. It causes less pain than other devices. The safety and 
acceptability of the device has been reported in various studies.  
   10% failure rate of outpatient endometrial sampling has been attributed 
to procedure as well as tissue failure. It is expected to obtain insufficient 
sample in women with atrophic endometrium. On the other hand in the 
presence of carcinoma, outpatient endometrial sampling is unlikely to fail 
in obtaining an adequate sample
4
.Though many studies have been 
reported from outside India about the usefulness of Pipelle type device in 
outpatient endometrial sampling, very few studies are available in India. 
This study was conducted to establish the effectiveness of   Pipelle   type 
of device as an outpatient procedure, so that number of traditional D&Cs   
under anesthesia can be reduced.  
 
  
AIM OF THE STUDY 
1. Comparing the results of  histopathological diagnosis of  Pipelle 
sampling with D&C. 
2. Comparing the adequacy of tissue for histopathological diagnosis of 
Pipelle sampling with D&C. 
3. To assess the feasibility of  Pipelle type of endometrial sampling as 
an outpatient procedure in AUB. 
 
 
 
 
 
 
 
 
 
 
 MATERIALS AND METHODS 
This is a prospective study comparing D&C and Pipelle type of 
endometrial sampling in patients with abnormal uterine bleeding.100 cases 
of AUB attending the outpatient clinic in the department of Obstetrics and 
Gynaecology, Coimbatore medical college, in the period of July 2011- July 
2012 were enrolled in this study. 
INCLUSION CRITERIA 
1. Age 30 years and above. 
2. Patients with AUB. 
3. Associated medical complication like HT and DM. 
4. Any endometrial thickness in premenopausal women and more  
than  4mm thickness in postmenopausal women. 
EXCLUSION CRITERIA 
1. Cervical stenosis. 
2. Lower genital tract infection. 
3. Extra uterine causes of AUB. 
4. Cervical causes of AUB. 
5. Endometrial thickness of ≤ 4mm in postmenopausal women. 
  A detailed history was taken and the patients were examined 
thoroughly and the findings were documented.  
The following preoperative investigations were done  
• Hemoglobin  
• Urine analysis 
• Blood sugar and urea  
• VDRL and HIV  
• USG 
• ECG,X-ray chest  
• Anesthetic assessment 
Injection Tetanus Toxoid 0.5ml was given 
 
 After getting the informed consent and proper selection of patient’s 
with AUB, endometrial sampling with Pipelle was done and then followed 
by formal D&C under anesthesia in theatre to the same patient the next 
day. Both specimens were sent to histopathology department and the 
results were compared. 
 
The patient’s bladder was emptied before the procedure. A speculum 
examination was done followed by bimanual pelvic examination. Pipelle 
endometrial device was introduced under aseptic precautions and without 
cervical dilatation . After creating negative pressure and with a rotatory 
movement it was withdrawn. The tip of the Pipelle device was cut. The 
piston was advanced and the sample was collected. 
Under anesthesia conventional dilatation and curettage was then 
done the next day. After bimanual pelvic examination uterine length was 
measured with uterine sound. After adequate cervical dilatation, 
endometrial curettage was done. The curettings were collected. 
The specimens obtained from the Pipelle sampling and D&C, were sent for 
histopathological reporting.  
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
Abnormal uterine bleeding (AUB) can arise from varying number 
of sources. AUB can affect 10-30 % of reproductive age women and upto 
50% of perimenopausal women
1
.Dysfuntional uterine bleeding is a 
diagnosis of exclusion after eliminating the causes of AUB
5 
. Goal of the 
clinical evaluation of AUB is to establish a diagnosis in the most efficient 
and least invasive manner possible. 
Abnormal Uterine Bleeding   can arise from one of the three broad 
etiologic categories. 
o First is due to organic lesions. 
o Second is dysfunctional uterine bleeding. 
o Finally systemic abnormalities. 
 
ORGANIC LESIONS OF AUB 
It includes pregnancy associated causes and structural causes. 
Structural causes are grouped as either focal (fibroids, polyps, 
adenomyosis) or diffuse (endometrial atrophy, hyperplasia or cancer and 
diffuse adenomyosis) lesions. 20%-40% of women have fibriods
6
. 
 
 
Table.1 Structural Causes  
Uterine polyp,leiomyoma ,adonomyosis 
Endometrial hyperplasia or endometrial carcinoma 
Mechanical cause-IUD 
Infections : endometritis, PID, tuberculosis 
Vascular (arteriovenous malformations) 
Partial outflow obstruction-asherman syndrome 
 
SYSTEMIC ABNORMALITIES OF AUB 
  It includes exogenous hormone adminstration (sex 
steroids,corticosteroids), coagulopathies, hepatic failure, chronic renal 
failure, endocrinopathies (hypothyroidism,hyperthyroidism,adrenal 
disorders,PCOS,obesity ,hypothalamo-pituitary disorders). 
 
DYSFUNCTIONAL UTERINE BLEEDING 
   It can be anovulatory or ovulatory. Anovulatory bleeding most 
commonly ocuurs in the extremes of reproductive age group, the cause 
being immaturity of the hypo-thalamo pituitary ovarian axis in the 
adolescent age group and  insensitve ovarian follicles in the 
perimenopausal age group. 
 
Table 2.  Causes of AUB in Reproductive age women
1
 
Pregnancy complications  
Anovulation associated 
Coagulation abnormalities 
Submucous, intramural fibroids  
Endometrial polyps 
Endometrial hyperplasia, carcinoma 
Infection and Medication related 
Intrauterine device complications 
 
The probability of encountering some of the pathogenic causes of 
AUB changes across adolescence, through reproductive period, to 
perimenopausal and menopausal period. The incidence of most structural 
lesions causing AUB, such as leiomyoma, polyps, endometrial carcinoma 
and adenomyosis rise with increasing age. Conversely, pregnancy 
complications as a source of AUB, become less frequent, as the incidence 
of pregnancy decreases across the reproductive age. Other conditions like 
infections, drug induced AUB and anovulation is encountered throughout  
life. Anovulatory bleeding and hormonal drug induced bleeding remains 
the most common source of non cyclical uterine bleeding.  
PERIMENOPAUSE 
 The older terms Perimenopause or climacteric refers to the time 
period in the late reproductive years. It is usually in the late 40s and early 
50s.  The recently preferred terminology is menopausal transition (MT).It 
is defined by the World Health Organization as the period beginning 2 to 8 
years prior to the final menstrual period (FMP)
7
. Treolar et al collected 
data of 2700 American women for 29 years with menstrual diaries. They 
assessed the changes which occurred with reproductive aging. 
 They concluded that, women in the age group of 20-40 years were 
characterized by regular cycles with a gradual fall in total cycle length of 2 
to 3 days. Cycles showed a tendency to become irregular after the age of 
40 years, primarily occurring approximately 7 years before reaching 
menopause
8
. 
Bleeding pattern in perimenopausal women 
 The most common clinical problem in peri and post menopausal 
women is AUB. It constitutes 70% of the hospital visits in this age group. 
There is no consistent normal uterine bleeding pattern during 
perimenopause. As like perimenarchial girls, dysfunction of the 
hypothalamo- pituitary- ovarian axis, resulting in anovulatory cycles 
becomes a more common finding in this group. The incidence of bleeding 
related to pregnancy and sexually transmitted diseases decreases with age.   
The risk of benign and malignant neoplastic growth  increases with age. 
       For example, setxler and colleagues
9 
(1990) analysed the charts 
of 500 perimenopausal women and studied the alterations in their 
menstrual flow. They concluded that 18 percent had menorrhagia or 
 metrorrhagia.One fifth of these 18% were due to premalignant or 
malignant disease. About 70% of perimenopausal women exhibited 
reduced frequency and quantity of uterine bleeding. Only 12 % stopped  
bleeding abruptly.10% of women with AUB in this age group can have 
endometrial carcinoma as in postmenopausal bleeding
10
.
.
Hence 
investigation is mandatory in cases presenting with risk factors for 
endometrial hyperplasia and carcinoma. All women who present with 
irrugular bleeding in this age group should undergo further evaluation as 
per the guideline
6,11
  
 Theories  
One of the many theories put forth to explain the mechanisms of 
abnormal perimenopausal bleeding is ovulation with a longer follicular 
phase. Estrogen level increases slowly during this phase. The endometrium 
is exposed to the proliferative stimulus of estrogen for a longer period of 
time resulting in thicker endometrium. The bleeding following  
progesterone withdrawal will be heavy and long
12
. This pattern is seen in 
some women early in perimenopause, even though there is an overall 
tendency for the follicular phase to shorten. The proliferation of 
endometrium continues until either the estrogen level declines resulting in 
bleeding, or the disorganized endometrium promotes unpredictable,  
irregular bleeding
13
. Perimenopausal women have been found to develop a 
relatively hyperestrogenic state with inadequate progesterone support, as 
seen by diminished luteal phase pregnanediol excretion
14,15 
During perimenopausal transition ample estrogen levels and 
prolonged endometrial stimulation in longer, anovulatory cycles contribute 
to the rising incidence of endometrial hyperplasia, growing myomas, and 
dysfunctional uterine bleeding (DUB) 
14,16,17,.
 . In one of the studies serum 
estradiol level was higher in women above 40 years presenting with 
menometrorrhagia (0.55 nmol/l vs 0.24 nmol/l) as compared to control 
group. But there was no difference in the FSH level
18
. 
A physiologic change in the length of menstruation is known to 
occur during the perimenopausal transition. Hence, investigation of all 
complaints of irregularity may not be warranted. Prolonged bleeding 
(lasting for more than 10 days) or intermenstrual bleeding (noncyclical) 
deserve workup
19
. 
 
Table 3. Causes of AUB in perimenoausal women
1 
Anovulation associated 
Focal uterine lesions (fibroids, polyps, adenomyosis) 
Diffuse uterine lesions(endometrial hyperplasia and cancer, diffuse 
adenomyosis) 
     
Although polyps and leiomyoma are the most common anatomic 
lesions, clinicians should keep in mind the possibility of endometrial 
cancer in the aging women. Approximately 170,000 new cases of 
endometrial cancer occurred in 1997
20
 .The incidence of endometrial 
carcinoma increases with age. Between 30 to 39 years the incidence was 
2.3 per 100000.In the perimenopausal age group (40-49 years), it increased 
to 36.2 per 100000.
21 
                       POSTMENOPAUSAL BLEEDING  
The term menopause refers to a point of time that follows 1 year 
after the cessation of menstruation. Evaluation of any patient presenting 
with bleeding after this period is mandatory
22
.The age of menopause is 
genetically determined, the average age being 51.5 years. Cause of 
postmenopausal bleeding may be  uterine or extra uterine
23
.
  
Clinical 
examination will reveal tumours of the cervix, vagina and vulva. Causes of 
uterine bleeding  are listed below. 
Table 4.Causes of postmenopausal Uterine Bleeding 
24
 
Causes Percentage % 
Endometrial atrophy 30 
Exogenous  estrogen 30 
Endometrial cancer 15 
Endometrial polyp 10 
Endometrial hyperplasia 5 
 
The most common endometrial finding in women with 
postmenopausal bleeding is endometrial atrophy, accounting for 60% to 
80% of such bleeding. Endometrial polyps account for 2% to 12% of 
postmenopausal bleeding. Polyps are often difficult to identify with office 
endometrial biopsy or curettage. Hysteroscopy, transvaginal 
ultrasonography or both may be useful adjuncts in identifying 
endometrial polyps.  
Estrogen therapy is an established risk factor for endometrial 
hyperplasia and cancer. The risk for endometrial cancer is 4 to 8 times 
greater in postmenopausal women receiving unopposed estrogen therapy, 
and the risk is proportional to the duration and the dose of estrogen. This 
risk can be decreased by the addition of a progestin to the estrogen, either 
cyclically or continuously. Endometrial biopsy should be performed as 
indicated to assess unscheduled bleeding or annually in women not taking 
a progestin. Endometrial hyperplasia occurs in 5% to 10% of patients 
with postmenopausal uterine bleeding. Endometrial cancer occurs in 10% 
of patients.   
Endometrial Cancer 
 Several risk factors for the development of endometrial cancer have 
been identified 
25,26,27,28,29,.
(Table 5). Most of these risk factors are related 
to prolonged, unopposed estrogen stimulation of the endometrium.
 
Table 5. Risk factors for Endomentrial cancer 
Characteristic Relative risk 
Nulliparity 2-3 
Late menopause 2-4 
Obesity 13 
Unopposed estrogen therapy 4-8 
Tamoxifen therapy 2-3 
Atypical endometrial hyperplasia 8-29 
HNPCC syndrome 20 
 
Endometrial carcinoma most often occurs in women in the sixth and 
seventh decades of life, at an average age of 60 years. 75% of cases occur 
in women older than 50 years of age. About 90% of women with 
endometrial carcinoma have vaginal bleeding or discharge as the only 
presenting symptom. Most women recognize the importance of this 
symptom and seek medical consultation within 3 months. Less than 5% of 
women diagnosed with endometrial cancer are asymptomatic.  
    Perimenopausal women with endometrial cancer invariably have 
abnormal uterine bleeding which is often characterized as 
menometrorrhagia   or cyclical bleeding that continues past the usual age 
of menopause.The diagnosis of endometrial cancer must be considered in 
premenopausal women if abnormal bleeding is persistent or recurrent or if 
obesity or chronic anovulation is present. 
Endometrial Hyperplasia 
Endometrial hyperplasia represents a spectrum of morphologic and 
biologic alterations of the endometrial glands and stroma, ranging from 
an exaggerated physiologic state to carcinoma in situ. Estrogen producing 
ovarian tumours, hormonal therapy, and endometrial cancer may be 
associated with endometrial hyperplasia resulting in abnormal bleeding. 
 
The risk of endometrial hyperplasia progressing to carcinoma is 
related to the presence and severity of cytological atypia. Kurman and 
colleagues retrospectively studied endometrial curettings from 170 
patients with untreated endometrial hyperplasia. They found that   1% of 
patients with simple hyperplasia, 3% of patients with complex 
hyperplasia, 8% of patients with atypical simple hyperplasia and 29% of 
patients with atypical complex hyperplasia progressed to carcinoma. 
Most of the hyperplasia seemed to remain stable (18%) or regress (74%).  
The premalignant potential of hyperplasia is influenced by age, 
underlying ovarian disease, endocrinopathy, obesity, and exogenous 
hormone exposure.
30,31 
 
 
Table 6.Classification of endometrial hyperplasia 
32
 
 
Type of Hyperplasia Progression to cancer 
(%) 
Simple (cystic without atypia) 1 
Complex (adenomatous without atypia) 3 
Simple(cystic with atypia) 8 
Complex(adenomatous with atypia) 29 
The diffuse lesion may be screened by endometrial imaging 
procedures, but final diagnosis relies on HPE of tissue. This can be 
accomplished by several sampling procedures. But the best method to 
establish and stage these diffuse lesions is complete histological evaluation 
of a hysterectomy specimen.  
Uterine Polyps 
By menopause, polyps are the most prevalent focal uterine lesions. 
Polyps also represent the most common cause of endometrial thickening, 
so they may present sonographically as either a focal or a diffuse lesion.  
This makes differentiation from hyperplasia and cancer of the 
endometrium problematic by TVUS alone.
33
Sonohysterography is a more 
reliable means of detecting polyps than TVUS.
34
 Risk factors for polyps 
overlap those for endometrial hyperplasia. The incidence rises with 
increasing age. 
Although not always  consistent, polyps tend to demonstrate 
homogenous echogenicity  with clear-cut borders and a  narrow stalk that 
often exhibits a single vessel source by Doppler  examination.  The polyp 
usually crosses the midline and is contained within the endometrial strip 
when TVUS is used. Polyps are easily missed by endometrial biopsy and 
even TVUS. Sonohysterography and hysteroscopy promise the best 
 sensitivities in detecting uterine polyps. Adenocarcinoma can arise within 
a polyp or sometimes present directly as polyps. So polyps should be 
removed when found in postmenopausal women. 
 
Atrophic Endometrium   
Atrophic endometrium is the most common cause of 
postmenopausal AUB 
35
.  Women with atrophic endometrium have a 
history of irregular spotting. In such a case the endometrium is scanty at 
biopsy and the HPE shows a proliferative phase. In some circumstances, 
sonography may eliminate the need for endometrial biopsy to make the 
diagnosis of atrophic endometrium as the source of AUB. An endometrial 
thickness (ET) of <4 mm by TVUS suggests endometrial atrophy. 
However, if the ET exceeds 4 mm or if the texture is heterogenous, then 
TVUS is inadequate and biopsy is required for diagnosis. 
 
 
 
 
 
 
THE DIAGNOSTIC PROCEDURES 
Each of the commonly used diagnostic procedures for AUB is 
reviewed here regarding the data concerning their accuracy, as well as 
practical matters and their potential roles. 
ENDOMETRIAL BIOPSY-D&C 
When the source of the bleeding is the uterine cavity, sampling of 
the endometrium for histopathological examination is mandatory. 
Although D&C continues to be a commonly performed procedure for 
both its diagnostic and therapeutic benefits, office endometrial biopsy can 
often expedite appropriate evaluation and therapy. Almost 40% of the 
endometrial cavity is not being curetted in a D&C, and therefore a 
possibility of missing the diagnoses is always there. In particular, most 
focal lesions (polyps and fibroids) are missed by D&C in postmenopausal 
women with AUB 
36
. 
The technique of dilatation 
The patient was placed in the lithotomy position. A tenaculum was 
used to hold the cervix and the uterine cavity was sounded. This provides 
confirmatory information about the position of the uterus and length of 
the uterine cavity. It also tells the angulation between the cervix and body 
of uterus.By this the complication of perforation can be avoided.  
3 or 4 mm Mathew Duncan dilator was first passed, then successively 
larger once were used.  For ordinary curettage, dilatation to 8 or 9 mm is 
enough. 
The technique of curettage of the uterus 
        After anesthesia patient is placed in lithotomy position. The bladder 
is emptied with a catheter. The pelvic organs are examined thoroughly 
before the patient is draped. The procedure includes a bimanual 
examination.  The anatomical details of the reproductive tract can be best 
appreciated under anesthesia. The vagina and perineum are cleaned in the 
usual way. Endocervical curettage is done before dilatation of cervical 
canal. The uterine cavity is then sounded to determine the length and the 
position. The cervical canal is dilated. Dilatation upto 8 or 9 mm is 
sufficient. A small  or medium sized, bluntly serrated curettw is then 
introduced into the uterus, and the entire uterine cavity is systematically 
curetted.  A firm and gentle scraping of anterior, lateral and posterior 
walls was done. Finally the top of the cavity is scraped with a side- to- 
side movement.  
The handle of the curette should never be held against the palm of 
the hands. It should be held like a pencil. The instrument should be held 
loosely while inserting into the uterine cavity until the fundus is reached.  
While withdrawing the curette, pressure is exerted against the uterine 
wall. It is drawn in an outward direction. After adequate curettage uterine 
vibration will be felt in the hand holding the curet. This is taken as a sign 
of adequate curetting. The curetting is collected in the gauze sponge.It 
should never be mashed. It should be picked with a smooth –tipped 
forceps and placed immediately in the fixative. 
Complications of Dilatation and Curettage 
Careful bimanual pelvic examination under anesthesia to assess the 
position and consistency of the uterus help in avoiding perforation. Care 
should be taken when the uterus is acutely anteflexed or retroflexed. 
Slight force is sufficient to cause perforation in post menopausal atrophic 
uterus. The resistance offered by the wall of the uterus will not be 
appreciated if perforation  has occurred. Uterine sound or dilator as a 
cause of perforation is less dangerous than sharp curette. Perforation may 
leed to bleeding or trauma to abdominal viscera. When perforation is 
detected, curettage should be discontinued. We have to watch carefully 
for signs of hemorrhage or infection.  
 
 
MacKenzia and Bibby reported, complications in 1.7% of cases of 
D&C.  According to McElin and colleagues, 0.5% of cases had 
postoperative febrile morbidity after the D&C procedure. Perforation  
occurred in 0.63% of cases. Other complications were infection and 
anesthesia related complications. If local pathology is detected while 
examination that should be treated before doing the procedure.    
 
 
 
 
 
 
  
 
 
 
 
Figure .1 Dilatation and Curettage 
 
 
 
 
 
 
 
 
 
 
ENDOMETRIAL SAMPLING –OUTPATIENT BIOPSY 
Outpatient endometrial biopsy has proven to be similar to the more 
invasive and costly D&C. Many instruments have been devised for the 
sampling of endometrial tissue and evaluation of the endometrial cavity. 
In 1882, Moriche obtained the first endometrial sample using a catheter 
and endometrial biopsy has been performed in an outpatient setting since 
1935. The 1970’s saw the introduction of Vabra curette followed by the 
Pipelle sampler in the 1980’s. 
Novak’s Curette 
Although this curette was initially devised to obtain a sample of the 
endometrium by suction and aspiration, it is most commonly used as a 
miniature curette that contained a serrated edge surrounding its biopsy 
aperture. The curette is about 5 mm in diameter and can usually be passed 
without dilatation through a small cervical canal, even in nulliparous 
women. Occasionally, the postmenopausal cervical canal is stenotic and 
difficult to penetrate. 
In a study conducted by Hofmeister
37
, office biopsy of 
endometrium was done for 23,202 patient belonging to all age groups . 
273 cases of endometrial carcinoma was detected (1.76%) ,32(14.28%)  
of whom  were asymptomatic. Hofmeister’s routine office endometrial  
biopsies using a modification  of the Novak and Randall curette provide 
one of the largest clinical experience of this instrument to date. 
Unfortunately, only patients who had continued uterine bleeding or who 
demonstrated an atypical pattern in the office biopsy were subjected to a 
complete curettage.  
Therefore, the true negative and false negative rate for the Novak 
type of curette in the detection of endometrial cancer has not been 
determined accurately.The main disadvantages with metal curettes  were 
patient discomfort, cost and procedural complications such as uterine 
perforation and infection. 
Silastic curette 
Because of the discomfort associated with passage of the Novak 
curette, newer silastic curettes have been developed. These have a smaller 
diameter (3 mm), are flexible and are often better tolerated by patients. 
They can be difficult to pass through a truly stenotic cervix because of 
their pliability. Often there is an accompanying syringe  attached which 
develops effective vacuum pressure to improve the size of the sample. 
Vabra   aspirator 
The Vabra aspirator has been used extensively over the past 20 
years. It is a disposable device and requires an external vacuum source,  
usually an electric pump. The cannula is commonly plastic, with a 4-mm 
diameter, although 2- and 3-mm stainless steel curettes are also available. 
A circumferential in- and - out motion is used to obtain a sample. 
Intravenous analgesia may be required to avoid discomfort during the 
procedure. Moreover, if the cervix is stenotic, larger cannulas may be 
difficult to introduce and cervical dilation may be necessary before 
sampling can be done. Vabra aspiration yields a sample comparable to 
that obtained with dilatation and curettage
38,39
 
Karman cannula and syringe  
The Karman cannula and syringe, unlike the Vabra aspirator, does 
not require an external vacuum source
40
.  The cannula is usually 4 to 6 
mm in diameter and is made of flexible plastic; it has two ports at the 
distal end. The cannula is used once and discardered, while the syringe, 
which produces the vacuum, may be reused. To obtain an adequate 
specimen, circumferential in - and - out motion is required. Intravenous 
analgesia may be necessary. In one small series
41
, this technique was 
compared with dilation and curettage and was found to have similar 
diagnostic accuracy. 
 
 
 
  
  Figure 2a.Novak’s Curette 
 
 
 
 
 
 
 
 
 Figure 2b.  Vabra 
Aspirator 
 
 
 
 
 
 
 
 
 
                 Figure 
2c.Karman Cannula 
 
PIPELLE 
Pipelle’s endometrial suction cannula does not require a syringe to 
develop negative pressure. It is a disposable plastic tube with a 3.1-mm 
outer diameter, an aspiration port at its tip and solid plastic obturator. The 
obturator fits so closely within the outer sleeve, that its slow withdrawal 
from the outer sleeve while withdrawing from the uterine cavity, causes 
sufficient suction to obtain an adequate endometrial specimen. 
        The Pipelle curette is introduced through the cervix to the uterine 
fundus. Vacuum  is created by pulling the obturator completely back to a 
self-retaining stop at the proximal end of the tube. The tube is then 
rotated continuously between the thumb and first finger as it is moved 
from the fundus to the internal os and then back to the fundus. The 
endometrial tissue adjacent to the side port is steadily drawn in by the 
negative pressure. The specimen is readily visible as it accumulates in the 
lumen of the tube. When the desired amount of tissue is obtained, the 
instrument is withdrawn, the distal tip is cut off and the obturator is 
advanced to expell the specimen directly into fixative transport medium. 
The Pipelle curette offers two advantages: it can traverse most 
cervical canals without prior dilation  and it is generally well tolerated 
without analgesia.  
             
FIGURE 3. PIPELLE CURETTE AND ITS SAMPLING PROCEDURE 
 
Figure 3 a.                  Figure3 b. 
 
                                                                   
 
 
Figure 3 c.                                                                                 Figure    3 d. 
                                   
PIPELLE ENDOMETRIAL SAMPLING – 
WHAT DOES STUDIES SAY 
Accuracy 
A review of the studies containing information regarding the 
accuracy of endometrial sampling using 18 different devices from 1966 to 
1999 , was  done by Dijkhuizen et al. He identified 39 informative studies 
involving 7914 women
42
.The studies included combinations of 
menopausal and/or perimenopausal women. Either subsequent formal 
D&C or hysterectomy was used as a reference compared with office 
endometrial biopsy. Diagnostic accuracy was better in menopausal women. 
Yet overall accuracy was good in all women, especially with the use of the 
Pipelle brand of curette, where sensitivity for endometrial carcinoma was 
99.6% and specifically was 91%. Sensitivity for atypical hyperplasia was 
81% with a specificity exceeding 98%  
A similar systematic review study by Clark et al, involving 1013 
patients from 11 primary studies, using 6 different commercial clinic 
biopsy instruments, identified good accuracy for a biopsy to pickup 
endometrial cancer, if the specimen was adequate for histopathological 
evaluation
43
. Failure rate put together for obtaining an adequate specimen 
was 7% and biopsy failure was more common in menopausal women.  
Endometrial biopsy results were also compared with D&C or hysterectomy 
taken as a standard reference. When a biopsy was positive for cancer, the 
post biopsy probability of endometrial cancer was 81.7 %    ( 95% CI; 
59.7-92.9) the pooled probability that a negative biopsy missed an 
endometrial cancer was 0.95(95%CI, 0.4-2.4). 
 If pathology is local, endometrial sampling is associated with a 
greater percentage of false –negative results, such as endometrial polyps. 
Guido and associates (1995) reported false negative results in 11 of 65 
patients (17%) undergoing Pipelle endometrial sampling for abnormal 
bleeding 
44
. Five of 11 patients had malignant tissue present only in 
endometrial polyps, and another 3 patients had disease localized to less 
than 5% of the endometrial surface. Overall, a positive result was accurate 
in the diagnosis of endometrial cancer whereas a negative result was not.  
Therefore, if an endometrial biopsy is negative in a situation where AUB 
continues, or if a biopsy cannot be obtained, then further more aggressive 
diagnostic efforts are warranted. 
Adequacy of sample 
In the study by Ben- Baruch et al (1994) Pipelle endometrial 
sampling was attempted in 174 women
45
. One hundred and seventy 
(98.8%) of the Pipelle aspirations attempted were successfully completed.  
Sufficient material for histological assessment was obtained in 154 
(90.6%)  women. In postmenopausal women, adequate specimens were 
obtained in 74 of 88 (84.1%) by Pipelle. In 45 cases the histological 
diagnosis of the endometrium obtained by Pipelle device was compared 
with sample obtained by D&C or hysterectomy done shortly thereafter. 
Histopathological finding were identical in 43out of 45 cases. Endometrial 
sampling with the Pipelle was well tolerated, occasionally causing slight 
discomfort. Shazia Fakhar  et al  
46
 reported an adequate  sample in 98% 
cases (total cases-100). Ajit Kuruvilla et al reported histological diagnosis 
were obtained in 68.6% of patients, in a sample size of 102 
cases.Insufficient sample was obtained in 32 patients and 22 of them had 
endometrial polyp and one had endometrial hyperplasia
47
. 
Smith –Bindman 
44
, 1998 reported that, a tissue sample inadequate 
for histological evaluation was obtained in 28% of biopsy attempts. 
Cost effectiveness 
Feldman et al 
49
 concluded that office biopsy was most cost effective 
initial evaluation procedure for patients of all age group presenting with 
AUB. It also seems to be cost effective procedure of choice for those 
patients with risk for endometrial carcinoma and complex hyperplasia 
presenting with postmenopausal bleeding for the first time. 
 
Pain related to the procedure 
Silver et al
50
 made a randomized study comparing Novak and 
Pipelle endometrial biopsy instruments with respect to quality of the 
biopsy obtained and pain related to the procedure. The instruments yielded 
biopsies of similar quality ( p = 0.856). Pain scores were lower for the 
Pipelle ( p= 0.001). The pathologist showed no preference when choosing 
Novak or Pipelle slides (x2=2.08.p=0.149). 
 
 
 
 
 
 
 
 
 
 
 
 
TRANSVAGINAL ULTRASOUND 
Screening for endometrial hyperplasia and carcinoma can be 
accompanied with transvaginal ultrasound as well. Sonographic picture 
and histopathology do not correlate, thereby making tissue diagnosis 
mandatory. In general, endometrial thickening, hyperechogenicity and 
heterogenous texture represent higher risk for cancer. Other features 
suggestive of cancer are   an enlarged uterus, fluid within the cavity, 
increased blood flow and an irregular interface of the endometrium   and 
myometrium. 
As the volume of the mass rises the chances of malignancy also 
increases. Given the same endometrial thickness, another general rule is 
that, increasing age increases the risk of endometrial malignancy. 
Therefore, ET measurements predict the risk of endometrial cancer in 
postmenopausal women more accurately than in premenopausal woman. 
Indeed, TVUS has demonstrated good accuracy for detecting endometrial   
carcinoma in postmenopausal women. 
A systematic analysis of 35 studies of TVUS among 5892 women 
with postmenopausal bleeding found prevalence rates of 13% for 
endometrial cancer and 40% for hyperplasia and / or polyps 
48
. Pooled 
results focused only on ET and not other sonographic characteristics of the  
endometrial lesions. Mean (±SD) ET measurements were 4 (±3) mm for 
polyps, 14 (±4) mm with hyperplasia, and 20 (±6) mm with carcinoma. 
The balance between sensitivity and specificity is dependent on the ET 
threshold used to define as abnormal. If 3 mm was used, sensitivity and 
specificity  were 98% and 38% respectively; but if 5 mm was used, the test 
characteristics were 92 %  an d 81% ;  and if 10 mm was designated as 
abnormal,the test characterstics were 66% and 79%.  The inference is that 
if the endometrial thickness exceeds 5mm, risk of cancer is 7.3% and it is 
<0.07% if the endometrial thickness  is ≤ 5mm
51
. 
Measurements of ET have been shown to be highly reproducible to both 
intra and interobserver measurement
52
. Nevertheless, ET measurements are 
not useful in predicting the presence of endometrial hyperplasia or 
carcinoma in premenopausal women. Persistent noncyclical bleeding, 
along with finding of ET in excess of approximately 11mm, should trigger 
concern in premenopausal women, especially in those with risk factors for 
endometrial carcinoma
34
. Risk factors include extended duration of AUB, 
chronic anovulation, estrogen exposure, nulliparity, diabetes, obesity, 
hypertension and tamoxifen use. TVUS may not be that useful in defining 
diffuse endometrial lesions in premenopausal women with AUB, but they 
are useful in detecting focal anatomic lesions of the uterus. 
 
SONOHYSTEROGRAPHY 
It is more expensive and invasive than TVUS and transabdominal 
ultrasonography. Another disadvantage is that optimally it must be done 
only in the proliferative phase after the menses so that menstrual tissue 
does not give false positive results .Thick secretary endometrium is likely 
to conceal focal lesions. Performing and interpreting sonohysterography 
takes special training as outlined by the American college of Obstetrics 
and Gynaecology (ACOG)
53 
Reinhold and Khalili have suggested 3 circumstances where SHG is 
recommended, assuming indeterminate TVUS and endometrial biopsy 
have been performed already: 
1. Thickened endometrium in the face of a non diagnostic biopsy. 
2. Indeterminate TVUS.  
3. Negative TVUS and biopsy findings but persistent bleeding. 
HYSTEROSALPINGOGRAPHY 
Hysterosalpingography (HSG) can reliably identify intracavitary 
masses. Occasionally subtle HSG findings can suggest a specific 
pathology. For example, when present, endometrial cancer tends to 
demonstrate irregular masses that are broad based. Another clue for  
endometrial cancer is limited uterine distensibility by contrast fluid. 
Disadvantages of HSG include the inability to identify diffuse lesions, the 
sites of attachment of intracavitary masses, intramural or subserosal lesions 
and the relative invasiveness (pain and radiation exposure) of the 
procedure. In addition, there is a risk that intracavitary blood clots 
associated with AUB will yield false positive findings. Therefore the 
primary role of hysterosalpingography for AUB has not been promoted. 
HYSTEROSCOPY  
Decreasing the caliber of hysteroscopy equipment with its attendant 
patient tolerability and lower cost has provided new diagnostic and even 
therapeutic possibilities in an office setting. Hysteroscopy enables accurate 
visualization of intracavitary masses but the same may not be true with 
regard to diffuse lesions. Hysteroscopy is an invasive procedure requiring 
specialized equipment and training to perform and interpret the findings. 
Hence it is not suitable as a primary screening tool for evaluating AUB.  
When the less invasive measures such as blind biopsy, sonography, and 
SHG are inadequate, hysteroscopy is indicated.As experience grows, 
ambulatory hysteroscopy may one day  change the currently popular          
2 - stage approach that uses screening TVUS in conjunction with blind 
endometrial sampling. 
 
DIAGNOSTIC STRATEGIES 
  Definitive diagnosis requires tissue confirmation; however routine 
endometrial sampling for all women with AUB is impractical. Instead 
skillful history, physical examination and directed laboratory work will be 
the most important initial diagnostic tools. The focus should be on 
determining those women with AUB who are at highest risk of 
endometrial cancer. During the reproductive time frame, these will 
typically be women with chronic anovulation. 
The ACOG has suggested endometrial sampling in the following 
patient with anovulatory bleeding 
53
. Even in adolescence, endometrial 
biopsy should be considered after 2 to 3 years of anovulatory bleeding, 
particularly in obese girls. Biopsy is indicated for all women suspected of 
anovulatory bleeding beyond 35 years of age,women who do not respond 
to medical therapy or who have risk factors for endometrial cancer . These 
ACOG recommendations do not incorporate criteria based upon any 
imaging studies. Endometrial sampling is also recommended in 
postmenopausal  bleeding of any amount, regardless of a finding of 
atrophic vaginitis, polyp, or urethral caruncle. Prior to hystrectomy 
endometrial sampling is mandatory to exclude endocervical or endometrial 
carcinoma in postmenopausal women.  
A panel of experts proposed elaborate diagnostic algorithms 
incorporating biopsy and imaging procedures  for the evaluation of 
postmenopausal bleeding
54
. In postmenopausal women these experts 
recommended that a threshold endometrial thickness of ≤5mm does not 
require endometrial sampling. Similar safe endometrial thickness threshold 
has not been substantiated for premenopausal women. It is difficult to 
clearly demarcate between hyperplasia, cancer, and ovulatory endometrial 
thickness measurements in premenopausal women. In this age group USG 
measurement of endometrial thickness is less useful when compared with 
clinical suspicion and risk factors, based on which biopsy is planned. 
In these women biopsy is based primarily on clinical suspicion and 
risk factors rather than on ultrasound measurements of endometrial 
thickness. A  grossly increased endometrial thickness (greater than 12mm) 
increases the risk of disease and is an indication for sampling, even when 
clinical suspicion of pathology is otherwise low 
55
. 
Moreover, there are substantial limitation to our knowledge about 
the accuracy, tolerability and cost efficiency of the available diagnostic  
tests for the evaluation of AUB in premenopausal women. Therefore, a 
universal linear evidenced-based algorithm incorporating imaging 
procedures for AUB cannot be assembled. 
In case of AUB , when a structural lesion is suspected TVUS is the 
first line of investigation which will help to detect and segregate the same. 
Even if previous endometrial sampling was nondiagnostic, TVUS may 
identify diffuse disease, and it is superior to blind sampling to detect focal 
lesions. 
Once anatomic lesions have been identified by examination or 
imaging, subsequent evaluation requires individualization. The prudent 
selection of appropriate tests depends upon their ability to characterize the 
anatomic lesions most highly suspected. Other variables that the clinician 
must balance include patient preference, available expertise, local cost and 
availability, risk and discomfort. Ultimately, test selection should be 
guided by the underlying principle that the results are capable of changing 
the clinical management of a patient in a meaningful way. Therefore, a 
clinician must be knowledgeable about the   characteristics of each 
potential diagnostic test for each type of structural lesion. 
 
 
 
 
 
HISTOPATHOLOGICAL DIAGNOSIS IN AUB 
Benign and Physiologic Causes of Abnormal Bleeding 
The underlying etiology for the abnormally bleeding patient is 
highly dependent upon age.
56
 The most common diagnosis is often the 
simplest, usually seen as proliferative endometrium, particularly in 
perimenopausal patients
57
(common in anovulation). Proliferative 
endometrium on histology shows tubular glands and the glandular lumens 
are round and regular. The endometrial stroma is compact and mitotic 
figures are common. In contrast, secretory glands show a simple epithelial 
lining. The glands are more undulant in their outline, secretions may be 
seen in the lumina, and the cells may contain subnuclear   vacuoles. The 
stroma contains abundant, eosinophilic (pink) cytoplasm. 
An endometrial polyp is more common than diagnosed. It is easier 
for the pathologist to diagnose this grossly in the intact uterine cavity after 
hystrectomy. During a curettage or biopsy, the polyp may be fragmented, 
and this destroys the architecture of the polyp. Important clues denoting a 
polyp are that of the polypoidal appearance seen histologically as three 
sided epithelium,dilated glands, fibrotic stroma and thick walled vessels. 
 
 
 
Pathological Causes of Abnormal Bleeding 
The strict definition of endometrial hyperplasia is an increase in 
glandular material per unit of stroma. Currently, most pathologist separate 
endometrial hyperplasia into simple, complex and atypical hyperplasia. 
Disordered proliferative endometrium is an intermediate diagnosis 
between proliferative type of endometrium and hyperplasia.  
The sequelae of changes seen in the endometrium due to unopposed 
oestrogen are as follows. There is considerable overlap between these 
entities. 
 
 
 
 
 
 
 
 
 
 
Proliferative 
Disordered Proliferative 
Simple Hyperplasia 
Complex Hyperplasia 
Atypical Hyperplasia 
Adenocarcinoma 
Disordered proliferative endometrium shows some glandular crowding 
and irregular glands with budding and branching. The glands affected by 
this are only focal and scattered throughout otherwise “normal” 
proliferative endometrium. It indicates unopposed estrogen stimulation to 
the endometrial lining. 
Simple hyperplasia indicates many crowded and often cystically dilated 
glands with some out pouching and budding, lined by pseudo stratified 
nuclei that show minimal atypia. 
Complex hyperplasia (“adenomatous hyperplasia”) involves more 
definitive architectural atypia. Endometrial gland gives an irregular 
definition and increasing architectural complexity at low power. Due to 
these features, the endometrium appears more crowded. 
Atypical hyperplasia (“complex atypical hyperplasia”, “atypical 
adenomatous  hyperplasia”) is the most worrisome of these entities and the 
least likely to be reversible .The diagnosis of atypical hyperplasia is based 
upon nuclear atypia. This includes nuclear enlargement and nuclear 
irregularity, a vesicular chromatin pattern with nucleoli, loss of nuclear 
polarity and frequent mitotic figures. 
 
 
Endometrial carcinoma in-situ is an older term implying a histological 
picture of well differtiated  adenocarcinoma, which has not yet invaded the 
stroma. Because the degree and depth of invasion is almost impossible to 
accurately tell on a limited and fragmented biopsy, most pathologists 
prefer to diagnose carcinoma with FIGO grade. Because the depth of 
invasion is best assessed on gross hysterectomy specimen, a diagnosis of 
“carcinoma in situ” on an endometrial biopsy or curettage does not 
guarantee the absence of invasion in the uterus. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 a. Proliferative Endometrium 
 
 
Figure 4 b . Secretory Endometrium 
 
 
Figure 4 c. Endometrial Polyp 
 
 
 
    
Figure 5a.Endometrial Hyperplasia 
 
     
 
 
 
 
 
 
 
                                      
 
 
 
 
Figure 5b.  Disordered  proliferative Endometrium 
 
 
 
 
 
 
 
  
        
 
 
 
 
 
Figure 5c .Endometrial Adenocarcinoma 
 
RESULTS AND ANALYSIS 
Hundred cases were included in the study period from 01/7/2011 to 
31/07/2012. All the patients underwent Pipelle endometrial sampling and 
dilatation and curettage.  
Table .7 Age distribution of the study sample  
 
Age group – years No. of patients Percentage (%) 
30-35 13 13 
36-40 29 29 
41-45 30 30 
46-50 18 18 
≥51  10 10 
Total 100 100 
  
Patients between 41-45 years constituted the maximum in our study. 
 
 
 
  
 
 
 
Figure.6 Age of the study group  
 
 
 
 
 
 
 
  
 
 
 
Table 8. Menopausal status of the patients 
 
 
 
 
 
Of the study group 70% (n=70) were premenopausal whereas 30% 
were postmenopausal (n=30). 
 
 
 
 
 
 No. of patients Percentage (%) 
Premenopausal 70 70 
Postmenopausal 30 30 
Total 100 100 
  
 
 
 
 
Figure .7 Menopausal status 
 
 
 
 
 
 
 
 
 
 Table 9.Presenting complaints of the patients 
Complaints No. of 
Patients 
Percentage 
(%) 
Post menopausal bleeding 30 30% 
Menorrhagia following amenorrhea 10 10% 
Menorrhagia 28 28% 
Metrorrhagia 20 20% 
Menometrorrhagia   12 12% 
Total 100 100% 
 
 Premenopausal patients included in this study had menorrhagia as 
their main complaint. Irregular bleeding was the second most common 
complaint in this group.  Most of the Postmenopausal patients had 
postmenopausal bleeding as their complaint.  
 
 
 
  
 
Figure.8 Presenting complaints 
  
 
 
 
 
 
 
 
Table 10. Distribution of patients in relation to endometrial thickness 
and menopausal status. 
 
Of the premenopausal patients 51(72.85%) had an endometrial 
thickness of more than 9mm. In the postmenopausal patients 13(43.3%) 
had endometrial thickness more than 9 mm. 
 
 
Endometrial 
thickness (mm) 
  
Premenopausal 
   
Postmenopausal 
 
Total 
≤6 8 1 9 
6.1-9.0 11 16 27 
9.1-12.0 10 10 20 
12.1-15.0 37 1 38 
15.1-18.0 3 1 4 
>18 1 1 2 
Total  70 30 100 
  
Figure.9 Distribution of patients in relation to endometrial thickness 
and menopausal status. 
 
 
 
 
 
 
 
 
 
 
 
COMPARISON BETWEEN D & C AND PIPELLE SAMPLING 
 
Table.11a  HPR with Pipelle and D&C sampling 
 
 HPR 
Obtained 
HPR not 
Obtained 
D&C 100(100%) 0 
Pipelle 88(88%) 12(12%) 
 
Table.11b  Sample adequacy with Pipelle and D&C  
 
  
Sufficient 
sample 
 
Insufficient 
sample 
D&C 100(100%) 0 
Pipelle 72(72%) 28(28%) 
 HPR was available in 88 of 100 patients in Pipelle. It was available 
in all cases of D&C. 
          On subjective perception, sufficient sample with Pipelle was 
obtained in 72 patient (72%) and 28 patient had insufficient 
sample(28%).Following D&C, sufficient sample was obtained in all 100 
patient (100%). Of the total 28 insufficient samples with Pipelle, HPR 
was available in 16 cases (57.2%). Of the remaining 12 patients, some 
amount of endometrial tissue was present in 11 cases, but   it was   
inadequate for the histopathologist to give a comment.          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure.10a) HPR with Pipelle and D&C sampling 
 
 
 
 
Figure.10b) Sample adequacy with Pipelle and D&C 
 
 
 
 
 
 
  
Table 12. Specific Histopathological condition reported with Pipelle 
and D&C   
 
Sample report D&C PIPELLE 
Adenocarcinoma 2(2%) 2(2%) 
Atrophic endometrium 2(2%) 2(2%) 
Complex hyperplasia 1(1%) 1(1%) 
Disordered proliferative 24(24%) 24(24%) 
Proliferative 38(38%) 30(30%) 
Secretory 33(33%) 29(29%) 
Blood clot  0 1(1%) 
Scanty endometrium 0 11(11%) 
Total 100(100%) 100(100%) 
 
 
 
 From analyzing the histopathological report obtained from Pipelle 
it became evident that except in one case, all other procedures, 99 out of 
100 procedures, were successful in collecting atleast some tissue from 
endometrium (99%). D&C was successful in collecting endometrium in 
all patients. 
When comparing the reports of HPE between the  D&C and Pipelle 
sampling, no case of endometrial adenocarcinoma or endometrial 
hyperplasia  were  missed out in Pipelle’s sampling.There was no 
discrepancy in  the reports   obtained from both types of sampling. 
Of those 12 cases  in Pipelle, where histopathology report  was not 
available, D&C  showed the following reports. 4 of  them  showed 
secretory  endometrium. Remaing showed proliferative endometrium 
with polypoidal changes. 
 
 
 
 
 
 
   
 
 
 
Figure11. Specific Histopathological Reports 
 
 
 
 
 
 
 
 
 
Table  13. Validity of Pipelle endometrial sampling for each 
endometrial condition  
Validity of 
Pipelle’s 
Sensitivity Specificity Positive 
predictive 
Value 
Negative 
predictive 
value 
Adenocarcinoma 100% 100% 100% 100% 
Hyperplasia 100% 100% 100% 100% 
Proliferative 78.9% 100% 100% 88.5% 
Secretory 87.8% 100% 100% 94.3% 
Atrophic 100% 100% 100% 100% 
 
Pipelle sampling showed 100% sensitivity and specificity with 
regards to diagnosis of carcinoma, hyperplasia and atrophic endometrium. 
With regard to secretory endometrium the corresponding values were 
87.8% and 100%. Whereas PPV, NPV were 100% and 94.3% 
respectively. Similarly, for proliferative endometrium sensitivity, 
specificity, positive predictive value and negative predictive value were 
78.9%, 100%, 100%, 88.5% respectively. 
 
FACTORS INFLUENCING THE FEASIBILITY AND EFFICACY 
OF PIPELLE SAMPLING 
Endometrial Sampling Procedure with Pipelle 
 Endometrial sampling procedure was termed subjectively as easy 
or tough by the doctor who performed the procedure, taking into 
consideration the time taken for the procedure and the discomfort it 
caused for the patient. 
Table 14. Ease of procedure with menopausal status 
 
  Menopause vs Sampling Menopause  
   Postmenopause Premenopause Total 
Sampling  Easy  Count 29 66 95 
% within Sampling 30.5% 69.5% 100.0% 
% within menopause 96.7% 94.3% 95.0% 
% of Total 29.0% 66.0% 95.0% 
 Tough  Count 1 4 5 
% within Sampling 20.0% 80.0% 100.0% 
% within menopause 3.3% 5.7% 5.0% 
% of Total 1.0% 4.0% 5.0% 
 Total  Count 30 70 100 
% within Sampling 30.0% 70.0% 100.0% 
% within menopause 100.0% 100.0% 100.0% 
% of Total 30.0% 70.0% 100.0% 
             Of all, only 5 were tough. Others were easy. Since the  percentage 
is less(5%) it is difficult to make statistically significant inference from 
this analysis. 4 of the 70 premenopausal patients had difficult procedure 
(5.7%), whereas it was one out of the 30 among postmenopausal patients 
(3.3%). χ
2
 = 0.2519 and the p value 0.617 which was >0.05. So the 
observed difference in the ease of procedure according to menopausal 
status was not statistically significant.  
 
Figure 12. Relationship of menopausal status with ease of procedure 
 
 
 
 
 
 
 
Table 14.Relationship of ease of procedure with mode of delivery 
 
 Parity vs Sampling 
Sampling  
 
  
Easy Tough Total 
Parity  
Nullip
arous 
 Count 3 2 5 
% within Parity 60.0% 40.0% 100.0% 
% within Sampling 3.2% 40.0% 5.0% 
% of Total 3.0% 2.0% 5.0% 
 
1  Count 13 0 13 
% within Parity 100.0% .0% 100.0% 
% within Sampling 13.7% .0% 13.0% 
% of Total 13.0% .0% 13.0% 
 
2  Count 54 3 57 
% within Parity 94.7% 5.3% 100.0% 
% within Sampling 56.8% 60.0% 57.0% 
% of Total 54.0% 3.0% 57.0% 
 
≥3  Count 25 0 25 
% within Parity 100.0% .0% 100.0% 
% within Sampling 26.3% .0% 25.0% 
% of Total 25.0% .0% 25.0% 
 
Total Count 95 5 100 
% within Parity 95.0% 5.0% 100.0% 
% within Sampling 100.0% 100.0% 100.0% 
% of Total 95.0% 5.0% 100.0% 
 
 
 
Chi square and p value of the above table are  χ
2
= 14.903 & 
p=0.002 respectively. Since the p value was < 0.05 it was statistically 
significant. Among nulliparous women tough sampling was seen in 40%. 
Among parous women those who delivered twice tough sampling was 
seen in 5.3%. 
 
Figure 13. Ease of procedure with parity. 
 
 
 
 
Table 15. Relationship between mode of delivery and ease of 
procedure 
  
  Sampling vs 
Delivery Sampling  
   Easy Tough Total 
Delivery  CS  Count 8 0 8 
% within Delivery 100.0% .0% 100.0% 
% within Sampling 8.4% .0% 8.0% 
% of Total 8.0% .0% 8.0% 
 
FTND  Count 84 3 87 
% within Delivery 96.6% 3.4% 100.0% 
% within Sampling 88.4% 60.0% 87.0% 
% of Total 84.0% 3.0% 87.0% 
 
Nullipa
rous 
 Count 3 2 5 
% within Delivery 60.0% 40.0% 100.0% 
% within Sampling 3.2% 40.0% 5.0% 
% of Total 3.0% 2.0% 5.0% 
 Total  Count 95 5 100 
% within Delivery 95.0% 5.0% 100.0% 
% within Sampling 100.0% 100.0% 100.0% 
% of Total 95.0% 5.0% 100.0% 
Chi square  and the p value of the above table was  χ
2
=13.757&     
p =0.001 respectively.since the p value was < 0.05 it was statistically 
significant. Nulliparous constituted 40% of the  tough procedure. 3.4% of 
those who delivered normally had tough procedure. 
 
 
 
Figure14. Relationship of Ease of procedure with mode of delivery 
 
 
 
 
Table 16. Relationship between the ease of procedure and HPR  
 
   HPR   
  Sampling vs HPR Obtained Not obtained Total 
Sampling  Easy  Count 83 12 95 
% within Sampling 87.4% 12.6% 100.0% 
% within code-HPR 94.3% 100.0% 95.0% 
% of Total 83.0% 12.0% 95.0% 
 
Tough  Count 5 0 5 
% within Sampling 100.0% .0% 100.0% 
% within code-HPR 5.7% .0% 5.0% 
% of Total 5.0% .0% 5.0% 
 Total  Count 88 12 100 
% within Sampling 88.0% 12.0% 100.0% 
% within code-HPR 100.0% 100.0% 100.0% 
% of Total 88.0% 12.0% 100.0% 
 
 
 
Easy procedure does not always mean that a histopathology report 
will be obtained. As observed in our study, of the 95 procedures termed 
easy, HPE report was not obtained in 12 cases.The chi-square test value 
was χ
2
=0.718 and the p value was 0.397.Since p value was > 0.05 the 
difference was not statistically significant.  
 
Figure 15. Relationship between ease of procedure with HPR  
 
 
 
 
 
 
 
 
Table 17.Relationship of ease of procedure with sample sufficiency  
  Sampling vs Procedure Procedure  
   Easy Tough Total 
  
Sample 
 Sufficient  
 
Count 67 5 72 
% within  Sample 93.1% 6.9% 100.0% 
% within procedure 70.5% 100.0% 72.0% 
% of Total 67.0% 5.0% 72.0% 
 
Scanty  Count 28 0 28 
% within Sample 100.0% .0% 100.0% 
% within procedure 29.5% .0% 28.0% 
% of Total 28.0% .0% 28.0% 
  Total Count 95 5 100 
% within  sample 95.0% 5.0% 100.0% 
% within procedure 100.0% 100.0% 100.0% 
% of Total 95.0% 5.0% 100.0% 
 
 An easy procedure doesn’t always result in obtaining an adequate 
sample.  Among the easy procedures sufficient sample was not obtained 
in 28 of 95 procedures (29.4%).  Though the procedure was termed 
tough, sufficient sample was obtained in all of the five cases. 
 
  
 
Figure 16.Relationship between ease of procedure with sample 
adequacy 
 
 
 
 
 
 
 
 
 
Table 18. Relationship of age with obtaining sufficient sample 
 
  Age vs. Sampling Sampling  
   Sufficient Scanty Total 
  Age  ≤50  
 
Count 67 23 90 
% within  age 74.4% 25.6% 100.0% 
% within sampling 93.1% 82.1% 90.0% 
% of Total 67.0% 23.0% 90.0% 
 
>50  Count 5 5 10 
% within age 50.0% 50.0% 100.0% 
% within sampling 6.9% 17.9% 10.0% 
% of Total 5.0% 5.0 % 10.0% 
  Total Count 72 28 100 
% within age 72.0% 28.0% 100.0% 
% within sampling  100.0% 100.0% 100.0% 
% of Total 72. 0% 28% 100.0% 
 
It was expected that inadequate sample will be associated with 
increasing age. In this study also, age group above 50 years had sample 
inadequacy rate of 50.0%. It was only 25.6% in the age group of less than  
or equal to 50 years. 
  
 
 
 
Figure 17.Relationship of age with adequacy of sample. 
 
 
 
 
  
 
 
 
 
 
 
  
 
Table 19 Relationship of menopausal status with obtaining sufficient 
sample 
  Menopause vs Tissue Sample Menopause  
   Postmenopause Premenopause Total 
Tissue 
Sample 
 Sufficient  
 
Count 16 56 72 
% within Tissue Sample 22.2% 77.8% 100.0% 
% within Premenopause 53.3% 80.0% 72.0% 
% of Total 16.0% 56.0% 72.0% 
 Scanty  Count 14 14 28 
% within Tissue Sample 50.0% 50.0% 100.0% 
% within Postmenopause 46.7% 20.0% 28.0% 
% of Total 14.0% 14.0% 28.0% 
 Total  Count 30 70 100 
% within Tissue Sample 30.0% 70.0% 100.0% 
% within Menopause 100.0% 100.0% 100.0% 
% of Total 30.0% 70.0% 100.0% 
 
 
  
If the patient is premenopausal the procedure yielded sufficient 
sample in 77.8% of the patients, whereas it gave sufficient sample only in 
50% of the patients if they were postmenopausal.The chi-square test 
value was  χ
2
= 7.407 and the p value was 0.006. Since the p value was 
<0.05, the observed difference in the sample sufficiency in relation to the 
menopausal status of the patient was statistically significant.  
 
Figure 18.Relationship of menopausal status with obtaining sufficient 
sample 
 
 
 
  
 
 
Table 20.Relationship between adequacies of sample with HPR  
  HPR vs Tissue Sample HPR  
   Obtained  Not Obtained Total 
Tissue 
Sample 
 Sufficient  
 
Count 72 0.0 72 
% within Tissue Sample 100.0% 0 100.0% 
% within HPR 81.8% 0.0% 72.0% 
% of Total 72.0% 0.0% 72.0% 
 Scanty  Count 16 12 28 
% within Tissue Sample 57.1% 42.9% 100.0% 
% within HPR 18.2% 100.0% 28.0% 
% of Total 16.0% 12.0% 28.0% 
 Total  Count 88 12 100 
% within Tissue Sample 88.0% 12.0% 100.0% 
% within HPR 100.0% 100.0% 100.0% 
% of Total 88.0% 12.0% 100.0% 
 
 
  
 
Sufficient sample always gives the histopathology report. In our 
study also histopathology report was obtained with all sufficient samples 
(72). Of the 28 procedures termed scanty sample, histopathology report 
was obtained in only 16 samples (57.2%). The chi-square test value was 
 χ
2
=35.065 and the p value was less than 0.05.So the observed difference 
in the sample sufficiency in relation to the HPE report was  statistically 
significant.          
Figure19.Reports of Scanty sample with Pipelle 
 
 
 
  
 
Table 21.Relationship of menopausal status with  HPR 
 
Menopause Obtained Not obtained 
Premenopausal 64 6 
Postmenopausal 24 6 
Total 41 12 
    
70 premenopausal patients HPR was available in 64 patients 
(91.4%).  But of the 30 post menopausal patients, report was available 
only in 24 (80%).  Applying the chi square test   χ
2
=2.597, the p value 
was 0.107. Since p value is more than 0.05 the difference is not 
statistically significant.   
Figure 20. Relationship of menopausal status with HPR 
  
Table 22. ROC curve-Histopathology report 
Variable ET 
Classification variable HPR OBTAINED ,HPR NOT OBTAINED 
 
Sample size  100 
Positive group HPR obtained 88 
Negative group HPR not obtained 12 
  
Significance level P (Area=0.5) <0.0001 
Area under the ROC curve (AUC 0.866 
Standard Error
a
 0.0348 
95% Confidence interval 0.784 to 0.926 
Significance level P (Area=0.5) <0.0001 
 
 
ROC curves were plotted to define the cut–off value for 
endometrial thickness which would enable successful histopathology 
reporting. In our studies the best cut-off value to predict the successful 
histopathology reporting of samples was 9mm. 
Figure 21. ROC curve for endometrial thickness 
  
 
 
 
 
 
 
 
DISCUSSION 
 
The most commonly used endometrial sampling methods are D&C 
and Pipelle sampling. In the majority of studies, the ability to diagnose 
endometrial carcinoma was used as a scale to assess the success rate of 
each method. When analyzing the various studies which compared the 
results of both D&C and Pipelle sampling, the Pipelle sampling was as 
effective and safe in diagnosing the endometrial lesions including 
hyperplasia and malignancy. The prime aim of our study is to evaluate 
Pipelle’s sampling as an effective, economic, safe and acceptable 
outpatient procedure.  
 
Demirkiran et al 
58
 followed a group of 673 patients who were 
evaluated with Pipelle endometrial biopsy, D&C and hysterectomy from 
2007-2009.  478 patients underwent Pipelle and D&C, 212 patients 
underwent Pipelle and hysterectomy and 161 patients underwent D&C 
and hysterectomy. Pipelle biopsy and D&C specimens were compared 
with regard to histopathological report  of each other and compared with 
hysterectomy specimens. They evaluated the statistically concordant rate 
with each other. They found  67%  between Pipelle and hysterectomy and 
70% between D&C and hysterectomy. Sensitivity of Pipelle biopsy in 
detection of hyperplasia and aytpia was 67% and 75% respectively.  
 
Sensitivity of D&C for detecting hyperplasia and atypia was 62% and 83 
%. NPV of pipelle biopsy and D&C was 99 % for malignancy. They 
concluded that Pipelle biopsy and D&C showed almost equal success rate 
in the diagnosis of endometrial pathologies. No method is adequate for 
diagnosing  focal endometrial pathologies.  Pipelle biopsy is  a cheaper 
and easier method. 
 
Fakhar et al
46 
evaluated 100 patient with AUB. D&C and pipelle 
were chosen as a method for sampling the endometrium and 
histopathology report were compared taking D&C as a gold standard. In 
98 of the 100 patients the sample was adequate as compared to 100 in 
D&C. Diagnosis of carcinoma, hyperplasia and secretory endometrium 
with pipelle showed a sensitivity and  specificity of 100%. Sensitivity and 
specificity for diagnosing proliferative endometrium was 94%,93% 
respectively. Two samples were inadequate by Pipelle. In both these 
cases D&C report showed polyp.The conclusion derived was that 
hyperplasia and malignancy could be detected with high sensitivity and 
specificity using Pipelle technique.  
 
 Tanriverdi et al
59
 studied the accuracy of the Pipelle sampling 
among 127 patients and compared it with dilatation and curettage. They 
concluded that Pipelle sampling should not be recommended  for those 
patients who carry an increased risk for endometrial carcinoma. 
 
In our study we could obtain sufficient samples in 88 cases using 
Pipelle device, whereas with D&C we could obtain adequate sample in all 
100 cases. Histopathological  findings of both the procedures were 
comparable. 100% sensitivity and specificity was obtained in diagnosing 
endometrial carcinoma and hyperplasia, which was comparable to the 
observation made by Fakhar and Saeed. 
 
 
 
 
 
 
 
Various factors contribute towards assessing the efficacy of Pipelle 
device as an outpatient procedure, in sampling the endometrium. 
Sufficient sample as from histopathology report 
It was observed from our study that  a histopathology report was 
available in 88 of the 100 case (88%). Other studies reported the success 
of Pipelle in obtaining an adequate sample to vary from 67% to 90.6%. 
Table 23 . Success in obtaining sufficient sample with Pipelle 
Study Year No  of 
patients 
Insufficient sample Success 
Machadoeta al
60
 2003 1535 16.09% 83.91% 
Ben-Baruch et al
45
 1994 172 9.4% 90.6% 
Bakour et al 
61 
2000 248 29.8% 70.20% 
Gordon et al 
62 
1999 100 33% 67% 
Epstein et al 
63 
2001 133 16% 84% 
Total  2228   
 
Of the 5 studies analyzed (Table 22), the total number of failure in 
obtaining adequate specimen for HPE were 392. The combined failure 
rate of all the studies came to 17.5%. The failure rate observed in our 
study was 12%, which was similar to the reported studies.  
Gordon et al
62
, in their study, reported an insufficient sample in 33  
out of 100 women of which 19 were women with  PMB (68%). Out of the 
30 women with postmenopausal bleeding in our study 7  had insufficient 
sample (23.3%). 
Bakour et al
61
 followed up 74 patients of 248 women who had 
insufficient tissue at Pipelle endometrial sampling. None of them had 
endometrial cancer or hyperplasia. In our study also nobody had 
endometrial cancer or hyperplasia in whom insufficient sample was 
obtained by Pipelle.  
Harmanliet al
64
 (2004) studied endometrial samples that were 
reported as inadequate. NPV in diagnosing endometrial carcinoma and 
hyperplasia was evaluated in these samples. As NPV was high they 
concluded that an insufficient office endometrial sample may be 
sufficient to rule out endometrial carcinoma. In our study, of the 11 
patients who had insufficient endometrium for histopathology with 
Pipelle device, none of them had endometrial hyperplasia or carcinoma 
when compared with the results obtained from D&C.  
 
 
Age and adequate tissue at sampling 
Williams et al
65
 in his study found that samples obtained were 
inadequate in women over 54 years.  
In our study (Table 18) age at or below 50 years was associated 
with higher success of sampling in relation to tissue obtained on 
histopathological examination.  
Menopausal Status 
Williams et al
65
 reported premenopausal status as very strongly 
associated with overall success of sampling. Study by Bakour et al
61
 
reported that postmenopausal status was significantly associated with 
insufficient sample to unadjusted analysis, but failed to show any 
difference when multivariate regression analysis was used.  
In our study  of the 70 premenopausal patients adequate tissue at 
histopathology examination was available in 64 patients (91.4%). But, of 
the 30 postmenopausal patients, report was available only in 24 (80%). 
The inference was not statistically significant. (p value = 0.107). 
 
 
 
 
Endometrial Polyp 
Gordon et al
62
 found that 50% of patients with an inadequate 
Pipelle sample had polyps or submucous fibroid. Fakher et al
46 
in their 
study on validity of Pipelle sampling of 100 cases found that both cases 
reported as inadequate on Pipelle were benign polyps on D&C report. 
In our study, it was noted that of the 12 patients who yielded 
insufficient sample with Pipelle device, definite diagnosis came as 
endometrial polyp in 8 cases. 
Endometrial thickness and insufficient sample 
Bakour et  al
61
 evaluated 248 women with AUB using Pipelle 
technique .74 insufficient sample were obtained and all the 74 were 
followed  with hysteroscopy and ultrasound for endometrial thickness. 
When the hysteroscopy finding was endometrial atrophy, the sample 
obtained by Pipelle was insufficient. Similarly, when the ET was below 
5mm,the sample was insufficient. 
In our study it was observed that endometrial thickness did not 
contribute significantly to the adequacy of tissue during sampling. Of the 
9 patients with endometrial thickness at or below 6 mm, adequate tissue 
for histopathological diagnosis was available in 8 cases.  
 
Parity  
 Williams et al 
65 
reported that failure of insertion of Pipelle was 
found to be more common with nulliparity (22%-nulliparous, 8%-
parous). Insufficient sample was seen in nulliparous women, 25% as 
compared  with parous women 5%. Bakour et al
 61 
found that there was no 
association between adequate sample and parity using multivariate 
regression analysis model. 
In our study there was no insertion failure in nulliparous and those 
not delivered vaginally. The sample did not have sufficient number of 
nulliparous women to detect whether a difference really existed.  
Endometrial Carcinoma 
 Between 1997-2000 Machado et al 
60 
analysed the pathology 
reports of 1535 patients with AUB. Pipelle technique was used  to collect 
the endometrial sample in both pre- and postmenopausal women. 168 
(10.9%) patients underwent D&C / hysterectomy at a later dates and the 
pathology report was compared with reports obtained with Pipelle. As the   
sensitivity, specificity and accuracy were comparable,it was inferred that 
atypical hyperplasia and endometrial cancer could be accurately 
diagnosed using Pipelle technique.  
 
In our study the patients detected to have endometrial cancers were only 
two. Both were correctly identified by the Pipelle technique. The 
sensitivity and specificity of 100% observed in our study correspond to 
the observations made by Dijkhuizen and Machodo. 
Adverse events associated with the procedure 
Critchley et al 
66
 reported minor adverse effects like patient distress 
occurred in 10% of women of pipelle sampling. Ben-Baruch et al 
reported that procedure was well tolerated causing only occasional slight 
discomfort.In our study, no major adverse effects were reported. Few 
patients mentioned mild pain but the procedure was well tolerated. (Mean 
pain score 1.3) 
Cost effectiveness 
Shazia Fakhar et al (2008)
46 
reported the cost per case was £39.46 
for dilatation and curettage as compared to £4.74 for the Pieplle. The cost 
included the procedure, anesthesia, surgery and inpatient charges.  
The cost of Pipelle sampling was Rs.250, compared to Rs.2000 for 
D&C, which was done under anesthesia .Although the higher inadequate 
tissue rate of Pipelle sampling was taken into consideration, Pipelle was 
certainly more cost effective than  D&C. 
 
  
LIMITATIONS OF STUDY 
 
    The number of patients enrolled in the study was less and so 
statistically significant inferences could not be made with regard to 
various factors. 
      
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
 
1) All patient underwent both Pipelle sampling  and D&C. D&C was 
considered as the definitive procedure for diagnosis 
2) Maximum number of patients were in the age group of 41-45 
years. 
3) 70% (70) were premenopausal and 30% were post menopausal 
(30). 
4) Premenopausal patient had menorrhagia as their main complaint. 
Most of the Post menopausal patients had post Menopausal 
bleeding as their complaint. 
5) 5 were nulliparous, 13 of them had delivered once, 57 of them 
delivered twice, 25 of them delivered three or more times.  
6) 87 of them had delivered vaginally, 8 of them delivered by 
caesarian section. 
7) An endometrial thickness of more than 9mm was present in 
72.85% of premenopausal patients.It was 43.3% in the 
postmenopausal patients. 
 
 
 
  IN PIPELLE SAMPLING 
 Sufficient sample was obtained in 72 patients and 28 patients had 
insufficient sample. With D&C, sufficient sample was obtained in all 
patients. 
 HPE Report obtained in Pipelle was only 88 %, whereas in D&C  it 
was  100%. 
  The most important factor associated with scanty tissue at Pipelle 
sampling was found to be endometrial polyp. 
 There was 100 % sensitivity and specificity of Pipelle for diagnosing 
endometrial carcinoma and  endometrial  hyperplasia. 
 4 out of the 70 premenopausal patients had difficult procedure 
(5.7%), where as it was 1 out of the 30 in postmenopausal patients 
(3.3%). 
 In nulliparous women 40% had tough procedure. 
 Among  those with easy procedure, sufficient sample was not 
obtained in 28 of 95 procedures (29.4%). 
 Elderly patients ( ≥50 years) had more inadequate sample rate 53.3%. 
 Sufficient sample was obtained in 77.8% in premenopasusal group, 
whereas in postmenopausal group it was only 50%. 
 In premenopausal patients HPR was available in 64 patients (91.4%).   
In postmenopausal patients, report was available only in 24 (80%). 
 HPE report was available in 16 out of 28 inadequate samples. 
 ROC curve gave the cut –off value for endometrial thickness of 9mm 
for successful histopathology reporting. 
  No major adverse events were associated with the procedure. All 
patients tolerated the procedure well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CONCLUSION 
 
 Endometrial sampling using Pipelle device is an easy and convenient 
method of getting tissue diagnosis. 
 It can be done as an outpatient procedure without any anesthesia, 
when compared to D&C which is done under anesthesia.  
 The sensitivity and specificity of this procedure in detecting 
endometrial hyperplasia and carcinoma were comparable with those of 
the standard procedure-D&C. 
 Pipelle’s sampling failed to detect endometrial polyp. 
 Considering all factors together, though Pipelle sampling failed to get 
sufficient sample in 12% of cases, comparing the high specificity in 
detecting endometrial hyperplasia and carcinoma, the cost 
effectiveness and anesthetic morbidity, intra and postoperative 
complications,Pipelle sampling can be used as  an effective screening 
procedure in the outpatient department. 
 
 
 
                         ABBREVIATIONS 
 
 
AUB   – Abnormal Uterine   Bleeding                  
D&C  - Dilatation and Curettage                          
HIV   –Human Immunodeficiency Virus             
USG   – Ultrasonogram                                        
ECG   –Electrocardiogram 
HT   –Hypertension 
DM  -Diabetes Mellitus 
PID  -Pelvic Inflammatory Disease 
MT   –Menopausal Transition 
FMP   –Final Menstrual Period 
PMB   –Post Menopausal Bleeding 
DUB  –Dysfunctional Uterine Bleeding 
FSH   –Follicle -Stimulating hormone 
HNPCC  –Hereditary Non Polyposis Colorectal Cancer 
HPE   –Histo Pathological Examination   
TVUS  –Transvaginal Ultrasonagraphy 
ET  -Endometrial Thickness 
CI  -Confidence interval  
P   –P Value 
SD  -Standard Deviation 
ACOG  –American College of Obstetrics and Gynaecology 
SHG  –Sonohysterography 
HSG  –Hysterosalpingography 
NPV  –Negative Predictive Value  
PPV   –Positive Predictive Value 
HPR   –Histo Pathological Report  
CS   –Cesarean Section 
FTND -Full Term Normal Delivery 
FIGO -International Federation of Gynecology and 
Obstetrics 
ROC  –Receiver Operating Characteristic curve  
AUC  -Area Under Curve  
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                                      PROFORMA 
 
Patient  name :                                                       Hospital no: 
Age   :                                                                DOA: 
Occupation : 
Religion  : 
Presenting complaints; 
 
1. Increased bleeding pv-                Duration of flow: 
                                                                Cycle length     : 
                                                                        Amount    : 
 
 
 
 
2. Dysmenorrhoea 
 
3. Lower abdomen pain 
 
4. Mass per abdomen 
 
 
 
 
 
 
Menstrual history 
Menarche:                                                             LMP 
                                                                              PMB 
Duration of flow:                                               Amount of flow: 
Cycles                : 
Menopause        : YES/NO                     Duration of menopause; 
Obstetric history 
Married/unmarried                                           If married, age at 
marriage 
Parity index 
Sterilisation 
 
Past history 
HT/DM                                                    
Personal history 
  
Treatment history:  
Any hormone therapy / Ablative procedures: 
 
 
 
 
 
EXAMINATION 
 
Height:                                                           Weight: 
General condition                                           
Per abdomen: 
 
 
Per speculum 
 
 
Pervaginum 
 
Investigations: 
 
 
 
USG    
Uterine size 
Endometrial thickness 
Ovaries 
Others                                                                              
abnormalities 
  
Pipelle Endometrial sampling:  
 
                                                                           Date:                                             
Procedure: Easy/tough 
Sample     : Sufficient/scanty 
Pain Score: 
 
HPE Report:                         Biopsy no: 
 
 
Dilatation and curettage:  
          Date: 
Per op findings     
                                                        
 
HPE report:                                                                   
                             
 
 
 
 

 
